CAR-T cell therapy for progressive multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have progressive multiple sclerosis (not relapsing-remitting).
- You need to have protection against shingles (from the Shingrix vaccine or prior infection).
- You must have antibodies to Epstein-Barr virus (EBV).
- Your organs (like heart, liver, kidneys, and lungs) must be working well enough.
- You cannot have certain past treatments, like stem cell transplant, CAR T, or anti-CD20 therapy within 9 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
This trial tests a new treatment called MB-CART2019.1, which uses your own immune cells to fight multiple sclerosis. It is for people with progressive or worsening MS who have not responded well to other treatments.
This trial tests a universal CAR-T cell treatment for people with autoimmune diseases of the nervous system that haven't responded to standard therapies. It aims to see if this therapy can help control diseases like neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multiple sclerosis.
This early-stage trial tests a new type of immune cell therapy (CAR T-cells) against several relapsed or hard-to-treat autoimmune diseases that affect the nervous system. The goal is to see if this treatment can safely calm the immune system and improve symptoms.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.